NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Price Target & More

$14.05 -0.54 (-3.70 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$14.05
Today's Range$13.83 - $14.78
52-Week Range$7.48 - $18.00
Volume782,282 shs
Average Volume408,287 shs
Market Capitalization$724.43 million
P/E Ratio-5.00
Dividend YieldN/A
Beta3.61

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Debt-to-Equity RatioN/A
Current Ratio3.00%
Quick Ratio3.00%

Price-To-Earnings

Trailing P/E Ratio-5.00
Forward P/E Ratio-5.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.61 million
Price / Sales433.28
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book5.38

Profitability

EPS (Most Recent Fiscal Year)($2.81)
Net Income$-128,980,000.00
Net MarginsN/A
Return on Equity-89.62%
Return on Assets-75.29%

Miscellaneous

Employees154
Outstanding Shares49,650,000

How to Become a New Pot Stock Millionaire

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics (NASDAQ:KPTI) released its earnings results on Thursday, March, 15th. The company reported ($0.80) EPS for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.14. The firm earned $1.53 million during the quarter, compared to the consensus estimate of $2.26 million. Karyopharm Therapeutics's revenue for the quarter was up 3163.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.65) EPS. View Karyopharm Therapeutics' Earnings History.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Karyopharm Therapeutics.

What price target have analysts set for KPTI?

8 brokers have issued twelve-month price targets for Karyopharm Therapeutics' stock. Their forecasts range from $18.00 to $26.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $21.00 in the next year. View Analyst Ratings for Karyopharm Therapeutics.

What are Wall Street analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
  • 1. Canaccord Genuity analysts commented, "We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT." (4/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "STORM Data. Top-line data from the STORM (Phase IIb) trial in penta- refractory multiple myeloma, which has been granted accelerated approval, are expected in late-April." (3/21/2018)
  • 3. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (3/21/2018)

Who are some of Karyopharm Therapeutics' key competitors?

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 55)
  • Dr. Sharon Shacham, Co-Founder, Co-Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer (Age 48)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Director and Member of Scientific Advisory Board (Age 57)
  • Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 59)
  • Mr. Michael J. Todisco, Acting Principal Financial & Accounting Officer (Age 53)

Has Karyopharm Therapeutics been receiving favorable news coverage?

Headlines about KPTI stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave media stories about the company an impact score of 46.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $14.05.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $724.43 million and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (KPTI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Karyopharm Therapeutics in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible upside of 49.47%. The high price target for KPTI is $26.00 and the low price target for KPTI is $18.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$20.25$17.4286$16.00
Price Target Upside: 49.47% upside29.31% upside65.83% upside39.98% upside

Karyopharm Therapeutics (NASDAQ:KPTI) Consensus Price Target History

Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018Canaccord GenuityReiterated RatingBuy$22.00LowView Rating Details
4/10/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$19.00 -> $20.00HighView Rating Details
4/2/2018Leerink SwannReiterated RatingOutperform -> Outperform$19.00HighView Rating Details
3/21/2018Cantor FitzgeraldSet Price TargetBuy$18.00LowView Rating Details
3/15/2018Robert W. BairdSet Price TargetBuy$22.00MediumView Rating Details
3/15/2018HC WainwrightBoost Price TargetBuy$26.00HighView Rating Details
3/2/2018Royal Bank of CanadaReiterated RatingBuy$22.00HighView Rating Details
10/13/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
4/5/2017WedbushReiterated RatingOutperform$14.00MediumView Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55N/AView Rating Details
5/27/2016Raymond JamesInitiated CoverageOutperform$13.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings History and Estimates Chart

Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.74)($0.63)($0.67)
Q2 20182($0.79)($0.59)($0.69)
Q3 20182($0.87)($0.60)($0.74)
Q4 20182($0.89)($0.61)($0.75)

Karyopharm Therapeutics (NASDAQ KPTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018        
3/15/2018Q4 2017($0.66)($0.80)$2.26 million$1.53 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.64)($0.65)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.64)($0.64)$0.23 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.6670)($0.71)$0.02 million$0.07 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.65)($0.65)$0.18 million$0.05 millionViewN/AView Earnings Details
11/7/2016Q316($0.81)($0.69)$0.18 million$0.05 millionViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)$0.18 million$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)$0.30 millionViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)$0.30 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)$0.30 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)$0.30 million$0.15 millionViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)$0.30 millionViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)$0.11 million$0.02 millionViewListenView Earnings Details
11/10/2014Q314($0.53)($0.61)$0.20 million$0.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.51)($0.55)$0.20 million$0.02 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.45)($0.46)$0.25 million$0.17 millionViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Karyopharm Therapeutics (NASDAQ:KPTI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.71%
Institutional Ownership Percentage: 62.45%
Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Michael KauffmanCEOSell10,000$14.79$147,900.00522,143View SEC Filing  
4/9/2018Sharon ShachamInsiderSell10,000$12.48$124,800.00723,510View SEC Filing  
3/19/2018Michael KauffmanCEOSell10,000$15.29$152,900.00522,143View SEC Filing  
3/12/2018Mansoor Raza MirzaDirectorSell2,500$17.01$42,525.002,500View SEC Filing  
3/7/2018Sharon ShachamInsiderSell10,000$16.15$161,500.00723,510View SEC Filing  
3/5/2018Christopher Brett PrimianoEVPSell2,500$16.03$40,075.004,881View SEC Filing  
2/20/2018Michael KauffmanCEOSell10,000$14.79$147,900.00View SEC Filing  
2/16/2018Christopher Brett PrimianoEVPSell2,500$15.01$37,525.00View SEC Filing  
2/7/2018Christopher Brett PrimianoEVPSell1,500$13.00$19,500.009,881View SEC Filing  
2/7/2018Sharon ShachamInsiderSell10,000$12.50$125,000.00723,510View SEC Filing  
1/18/2018Michael KauffmanCEOSell10,000$10.09$100,900.00522,143View SEC Filing  
1/8/2018Sharon ShachamInsiderSell10,000$10.08$100,800.00723,510View SEC Filing  
12/18/2017Michael KauffmanCEOSell10,000$9.16$91,600.00522,143View SEC Filing  
12/12/2017Christopher Brett PrimianoSVPSell27,042$10.28$277,991.7611,381View SEC Filing  
12/7/2017Sharon ShachamInsiderSell10,000$10.39$103,900.00View SEC Filing  
11/7/2017Christopher Brett PrimianoSVPSell4,958$11.25$55,777.50View SEC Filing  
10/2/2017Christopher Brett PrimianoSVPSell1,500$12.00$18,000.00View SEC Filing  
10/2/2017Mansoor Raza MirzaDirectorSell2,000$12.00$24,000.00View SEC Filing  
9/15/2017Christopher Brett PrimianoSVPSell2,000$11.00$22,000.0012,881View SEC Filing  
9/15/2017Mansoor Raza MirzaDirectorSell2,882$11.00$31,702.002,882View SEC Filing  
9/11/2017Mansoor Raza MirzaDirectorSell118$11.00$1,298.00118View SEC Filing  
8/29/2017Christopher Brett PrimianoSVPSell2,195$10.00$21,950.00View SEC Filing  
6/26/2017Christopher Brett PrimianoSVPSell805$10.03$8,074.15View SEC Filing  
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.5414,691View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.748,568,744View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.618,605,818View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.008,641,359View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.758,661,359View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.048,713,878View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.368,713,878View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.008,713,878View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.068,772,060View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.288,873,932View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.008,923,932View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.008,967,732View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.328,980,000View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.0064,636View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Karyopharm Therapeutics (NASDAQ KPTI) News Headlines

Source:
DateHeadline
Michael Kauffman Sells 10,000 Shares of Karyopharm Therapeutics (KPTI) StockMichael Kauffman Sells 10,000 Shares of Karyopharm Therapeutics (KPTI) Stock
www.americanbankingnews.com - April 20 at 7:40 PM
$4.59 Million in Sales Expected for Karyopharm Therapeutics (KPTI) This Quarter$4.59 Million in Sales Expected for Karyopharm Therapeutics (KPTI) This Quarter
www.americanbankingnews.com - April 18 at 1:48 AM
Karyopharm Therapeutics (KPTI) Downgraded to "Hold" at Zacks Investment ResearchKaryopharm Therapeutics (KPTI) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:47 PM
Karyopharm Therapeutics (KPTI) Expected to Announce Earnings of -$0.67 Per ShareKaryopharm Therapeutics (KPTI) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - April 16 at 11:08 PM
2 Small Biotechs To Buy This Week2 Small Biotechs To Buy This Week
seekingalpha.com - April 16 at 5:24 PM
BidaskClub Lowers Karyopharm Therapeutics (KPTI) to Strong SellBidaskClub Lowers Karyopharm Therapeutics (KPTI) to Strong Sell
www.americanbankingnews.com - April 14 at 10:19 PM
3 Things In Biotech, April 11: Spectrums Entree In EGFR, Karyopharms Rush, Oncolytics Looks On3 Things In Biotech, April 11: Spectrum's Entree In EGFR, Karyopharm's Rush, Oncolytics Looks On
seekingalpha.com - April 12 at 5:38 PM
Karyopharm Therapeutics (KPTI) Upgraded to Sell at BidaskClubKaryopharm Therapeutics (KPTI) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 9:30 PM
Karyopharms Myeloma Candidate Gets Fast Track DesignationKaryopharm's Myeloma Candidate Gets Fast Track Designation
www.msn.com - April 11 at 5:31 PM
Karyopharm's Myeloma Candidate Gets Fast Track DesignationKaryopharm's Myeloma Candidate Gets Fast Track Designation
finance.yahoo.com - April 11 at 5:31 PM
Jefferies Group Reiterates Buy Rating for Karyopharm Therapeutics (KPTI)Jefferies Group Reiterates Buy Rating for Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - April 11 at 1:33 PM
Karyopharm Therapeutics (KPTI) Receives Buy Rating from Canaccord GenuityKaryopharm Therapeutics (KPTI) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - April 10 at 9:26 PM
Karyopharm Therapeutics (KPTI) Insider Sharon Shacham Sells 10,000 SharesKaryopharm Therapeutics (KPTI) Insider Sharon Shacham Sells 10,000 Shares
www.americanbankingnews.com - April 10 at 7:11 PM
Pre-Open Movers 04/10: (PAY) (WATT) (SPPI) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)Pre-Open Movers 04/10: (PAY) (WATT) (SPPI) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)
www.streetinsider.com - April 10 at 5:29 PM
Karyopharm Therapeutics (KPTI) Price Target Increased to $20.00 by Analysts at JPMorgan ChaseKaryopharm Therapeutics (KPTI) Price Target Increased to $20.00 by Analysts at JPMorgan Chase
www.americanbankingnews.com - April 10 at 10:57 AM
Karyopharm Therapeutics (KPTI) Says Selinexor Received FDA Fast Track Designation for Treatment of Patients with Penta-Refractory Multiple MyelomaKaryopharm Therapeutics (KPTI) Says Selinexor Received FDA Fast Track Designation for Treatment of Patients with Penta-Refractory Multiple Myeloma
www.streetinsider.com - April 10 at 8:27 AM
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple MyelomaKaryopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
finance.yahoo.com - April 10 at 8:27 AM
Karyopharm Therapeutics shares surge 8% after company wins fast-track designation for cancer drugKaryopharm Therapeutics shares surge 8% after company wins fast-track designation for cancer drug
finance.yahoo.com - April 10 at 8:27 AM
ValuEngine Downgrades Karyopharm Therapeutics (KPTI) to SellValuEngine Downgrades Karyopharm Therapeutics (KPTI) to Sell
www.americanbankingnews.com - April 9 at 6:25 PM
Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI)Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI)
www.zacks.com - April 6 at 8:27 AM
Karyopharm Therapeutics (KPTI) Given Consensus Recommendation of "Buy" by AnalystsKaryopharm Therapeutics (KPTI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 1:21 PM
Q1 2018 Earnings Estimate for Karyopharm Therapeutics (KPTI) Issued By Leerink SwannQ1 2018 Earnings Estimate for Karyopharm Therapeutics (KPTI) Issued By Leerink Swann
www.americanbankingnews.com - April 4 at 7:36 AM
Karyopharm Therapeutics (KPTI) Downgraded by BidaskClubKaryopharm Therapeutics (KPTI) Downgraded by BidaskClub
www.americanbankingnews.com - April 3 at 11:00 AM
Leerink Swann Initiates Coverage on Karyopharm Therapeutics (KPTI)Leerink Swann Initiates Coverage on Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - April 2 at 10:12 AM
Karyopharm Therapeutics Inc (KPTI) Expected to Post Quarterly Sales of $4.59 MillionKaryopharm Therapeutics Inc (KPTI) Expected to Post Quarterly Sales of $4.59 Million
www.americanbankingnews.com - April 2 at 5:24 AM
Zacks Investment Research Downgrades Karyopharm Therapeutics (KPTI) to HoldZacks Investment Research Downgrades Karyopharm Therapeutics (KPTI) to Hold
www.americanbankingnews.com - April 1 at 7:00 PM
 Analysts Anticipate Karyopharm Therapeutics Inc (KPTI) to Post -$0.67 Earnings Per Share Analysts Anticipate Karyopharm Therapeutics Inc (KPTI) to Post -$0.67 Earnings Per Share
www.americanbankingnews.com - March 31 at 3:22 AM
BidaskClub Lowers Karyopharm Therapeutics (KPTI) to BuyBidaskClub Lowers Karyopharm Therapeutics (KPTI) to Buy
www.americanbankingnews.com - March 24 at 1:54 PM
Karyopharm Therapeutics (KPTI) Downgraded by Zacks Investment Research to "Sell"Karyopharm Therapeutics (KPTI) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 23 at 11:52 PM
Cantor Fitzgerald Comments on Karyopharm Therapeutics Incs FY2018 Earnings (KPTI)Cantor Fitzgerald Comments on Karyopharm Therapeutics Inc's FY2018 Earnings (KPTI)
www.americanbankingnews.com - March 23 at 10:38 AM
Karyopharm Therapeutics (KPTI) Earns Buy Rating from Cantor FitzgeraldKaryopharm Therapeutics (KPTI) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 21 at 12:07 PM
Karyopharm Therapeutics Inc (KPTI) CEO Sells $152,900.00 in StockKaryopharm Therapeutics Inc (KPTI) CEO Sells $152,900.00 in Stock
www.americanbankingnews.com - March 20 at 8:10 PM
Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting - GlobeNewswire (press release)Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting - GlobeNewswire (press release)
globenewswire.com - March 20 at 8:28 AM
Karyopharm to Present Preclinical Data at the American Association ... - NasdaqKaryopharm to Present Preclinical Data at the American Association ... - Nasdaq
www.nasdaq.com - March 20 at 8:28 AM
Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual MeetingKaryopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - March 19 at 5:17 PM
Research Analysts Offer Predictions for Karyopharm Therapeutics Incs Q1 2018 Earnings (KPTI)Research Analysts Offer Predictions for Karyopharm Therapeutics Inc's Q1 2018 Earnings (KPTI)
www.americanbankingnews.com - March 19 at 1:40 AM
Edited Transcript of KPTI earnings conference call or presentation 15-Mar-18 12:30pm GMTEdited Transcript of KPTI earnings conference call or presentation 15-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 8:18 AM
JPMorgan Chase & Co. Raises Karyopharm Therapeutics (KPTI) Price Target to $19.00JPMorgan Chase & Co. Raises Karyopharm Therapeutics (KPTI) Price Target to $19.00
www.americanbankingnews.com - March 16 at 11:34 AM
Karyopharm Therapeutics (KPTI) CEO Michael Kauffman on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaKaryopharm Therapeutics' (KPTI) CEO Michael Kauffman on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 8:20 AM
Robert W. Baird Analysts Give Karyopharm Therapeutics (KPTI) a $22.00 Price TargetRobert W. Baird Analysts Give Karyopharm Therapeutics (KPTI) a $22.00 Price Target
www.americanbankingnews.com - March 15 at 7:06 PM
Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent ProgressKaryopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
finance.yahoo.com - March 15 at 6:12 PM
Karyopharm Therapeutics (KPTI) PT Raised to $26.00Karyopharm Therapeutics (KPTI) PT Raised to $26.00
www.americanbankingnews.com - March 15 at 5:46 PM
Cantor Fitzgerald Reiterates "$18.00" Price Target for Karyopharm Therapeutics (KPTI)Cantor Fitzgerald Reiterates "$18.00" Price Target for Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - March 15 at 4:54 PM
Karyopharm Therapeutics (KPTI) Posts  Earnings Results, Misses Estimates By $0.14 EPSKaryopharm Therapeutics (KPTI) Posts Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - March 15 at 8:59 AM
Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress - GlobeNewswire (press release)Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:16 AM
Should Karyopharm Therapeutics Inc’s (NASDAQ:KPTI) Recent Earnings Decline Worry You?Should Karyopharm Therapeutics Inc’s (NASDAQ:KPTI) Recent Earnings Decline Worry You?
finance.yahoo.com - March 15 at 8:16 AM
Karyopharm Therapeutics Inc (KPTI) Director Sells $42,525.00 in StockKaryopharm Therapeutics Inc (KPTI) Director Sells $42,525.00 in Stock
www.americanbankingnews.com - March 14 at 8:28 PM
 Brokerages Expect Karyopharm Therapeutics Inc (KPTI) Will Announce Earnings of -$0.66 Per Share Brokerages Expect Karyopharm Therapeutics Inc (KPTI) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - March 13 at 11:10 PM
Canaccord Genuity Boosts Karyopharm Therapeutics (KPTI) Price Target to $22.00Canaccord Genuity Boosts Karyopharm Therapeutics (KPTI) Price Target to $22.00
www.americanbankingnews.com - March 12 at 11:26 AM
Karyopharm Therapeutics Inc (KPTI) Given Average Recommendation of "Buy" by BrokeragesKaryopharm Therapeutics Inc (KPTI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 11 at 12:14 PM

SEC Filings

Karyopharm Therapeutics (NASDAQ:KPTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Karyopharm Therapeutics (NASDAQ:KPTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Karyopharm Therapeutics (NASDAQ KPTI) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.